Compare LSE & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSE | AARD |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | China | United States |
| Employees | N/A | 40 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 85.7M |
| IPO Year | N/A | N/A |
| Metric | LSE | AARD |
|---|---|---|
| Price | $4.11 | $3.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 27.2K | ★ 127.2K |
| Earning Date | 01-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $61.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.20 | $3.35 |
| 52 Week High | $7.40 | $17.94 |
| Indicator | LSE | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 44.36 |
| Support Level | N/A | $3.38 |
| Resistance Level | $5.35 | $4.39 |
| Average True Range (ATR) | 0.76 | 0.29 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 19.31 | 72.22 |
Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment, oil and gas engineering technical services, new energy production and operation, and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment, which supplies various equipment, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.